Universal Navigation

Join or Renew Your Membership Join Now

S4 - Clinical Trials in Movement Disorders

Event Time:	Sunday May 5, 2019 1:00 pm to 3:00 pm
Topic(s):	Movement Disorders
Director(s):
Description:
Completion Message:
CME Credits:	2
Core Competencies:

Program Speakers - Tentative
Start/End Time	Title	Faculty
2:40 PM - 3:00 PM	Q&A Panel with Authors	Faculty

Disclosures
Speaker	Disclosure

Abstract Presenters
Start Time	Pub.	Title	Presenter
1:00 PM	001	A First in Human Study of PBT434, a Novel Small Molecule Inhibitor of a-Synuclein Aggregation	Disclosure: Dr. Stamler has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Auspex Pharmaceuticals.
1:00 PM	002	Safety, tolerability and pharmacokinetics of oral venglustat in Parkinson’s disease patients with a GBA mutation	Disclosure: Dr. Fischer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi Genzyme. Dr. Fischer has received compensation for serving on the Board of Directors of Sanofi Genzyme.
1:00 PM	003	Once-Daily Opicapone Increases ON-Time in Patients with Parkinson’s Disease: Results from Two Phase 3 Studies	Disclosure: Dr. LeWitt has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dr. LeWitt has served as a paid consultant for NeuroDerm Ltd. Dr. LeWitt has served as consultant or advisor (non-paid) for Acorda Therapeutics, Adamas Pharmaceuticals, Biogen Inc., Britannia, Bukwang Pharmaceutical Co., Cavion Pharma, Chrono Therapeutics, Intec Pharma, Merz Pharmaceuticals, Parkinson Study Group, Pfizer Inc., Prexton Therapeutics, Revance Therapeutics, Sage Therapeutics, SynAgile Corporation, Titan Pharmaceuticals, USWorldMeds, and Voyager Therapeutics, and has received speaker honoraria from The International Parkinson’s Disease and Movement Disorders Society, Lundbeck, USWorldMeds, and the World Parkinson Congress.. Dr. LeWitt has received personal compensation in an editorial capacity for Dr. LeWitt is compensated for services as Editor-in-Chief of Clinical Neuropharmacology and serves without compensation on the editorial boards of Journal of Neural Transmission, Translational Neurodegeneration, and Journal of Parkinson’s Disease. Dr. LeWitt has received research support from The Parkinson’s Disease and Movement Disorders Program that Dr. LeWitt directs has received clinical research grant support (for conducting clinical trial and other research) from Accorda Therapeutics, Biotie Therapies, Inc., Intec Pharma, Lundbeck, The Michael J. Fox Foundation for Parkinson’s Research, Roche Pharmaceuticals, Sunovion Pharmaceuticals, and USWorldMeds.
1:00 PM	004	Levodopa-Carbidopa Intestinal Gel for the Treatment of Motor Fluctuations and Dyskinesia in Patients with Advanced Parkinson’s Disease in a ‘Real World’ Setting: Results of an Interim Analysis of the Multinational Observational Long-term Study DUOGLOBE	Disclosure: Dr. Standaert has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Serina Therapeutics, Abbvie Inc., the Michael J. Fox Foundation for Parkinson Research, The International Parkinson Disease and Movement Disorder Society, The Parkinson Foundation, the National Institutes of Health, Oregon Health Sciences University, Voyager Therapeutics, Blue Rock Therapeutics, Clintrex LLC, Revivo Therapeutics, Sanofi-Adventis Research and Development, and US Department of Justice. Dr. Standaert has received license feed payments, royalties, or contractual rights from McGraw Hill, Inc. Dr. Standaert has received research support from Abbvie, Inc., Avid Radiopharmaceuticals, the American Parkinson Disease Association, the Michael J. Fox Foundation for Parkinson Research, Alabama Department of Commerce, the Bachmann-Strauss Dystonia; Parkinson Foundation, and NIH grants.
1:00 PM	005	SYN120 (a dual 5-HT6/5-HT2A antagonist) study to evaluate safety, tolerability, and efficacy in Parkinson’s disease dementia (SYNAPSE): Phase 2a study results	Disclosure: Dr. Fernandez has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with American Osteopathic Association, Cleveland Clinic, South Alabama Medical Science Foundation Thoraxx Clinical Communications, and UMA Education, as a speaker in CME events. Acorda Therapeutics, Bial Neurology, Denali Therapeutics, Pfizer, Partners Healthcare System, Parkinson Study Group, Revance, Sun Pharmaceutical Industries, Sunovion Research and Development Trust as a consultant. . Dr. Fernandez has received royalty, license fees, or contractual rights payments from Demos Publishing, Cambridge University Press. Dr. Fernandez has received research support from Abbvie, Biotie/Acorda Therapeutics, Michael J. Fox Foundation, Movement Disorders Society, NIH/NINDS, Parkinson Study Group, Rhythm, Sunovion.
1:00 PM	006	Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy	Disclosure: Dr. Ali has nothing to disclose.
1:00 PM	007	Long-term Efficacy and Safety of IncobotulinumtoxinA Treatment for Sialorrhea	Disclosure: Dr. Pagan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sunovion, Teva, Acadia, Adamas, AbbVie, Medtronic, US Word Meds, Merz.
1:00 PM	008	Efficacy Result from a Phase 2, Double-Blind, Placebo-Controlled Study of CX-8998 a State-Dependent T-Type Calcium (Cav3) Channel Modulator in Essential Tremor Patients (T-CALM)	Disclosure: Dr. Papapetropoulos has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Cavion Inc. Dr. Papapetropoulos holds stock and/or stock options in Apptomics Inc., which sponsored research in which Dr. Papapetropoulos was involved as an investigator. Dr. Papapetropoulos holds stock and/or stock option sin Cavion Inc.
1:00 PM	009	Long-Term Treatment With Deutetrabenazine Is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From an Open-Label Extension Study	Disclosure: Dr. Hauser has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie Inc., Acorda Therapeutics, Academy for Continued Healthcare Learning, Acadia Pharmaceuticals, Inc., Adamas Pharmaceuticals, AstraZeneca, Back Bay Life Science, Biotie Therapies, Bracket, Cerecor, Inc., ClearView Healthcare Partners, ClinicalMind Medical and Therapeutic Communications, Cowen and Company, Cynapsus Therapeutics, Decision Resources Group, Eli Lilly & Company, eResearch Technology, Inc., Expert Connect, Extera Partners, Gerson Lehrman Group (GLG), Guidepoint Global, GE Healthcare, Globe Life Sciences, Health Advances, HealthLogix, Health and Wellness Partners, Huron Consulting Group, Impax Laboratories, Intec Pharma Ltd., Jazz Pharmaceuticals, Kyowa Kirin Pharmaceutical Development, Ltd., LCN Consulting, LifeMax, Lundbeck LLC, The Lockwood Group, MEDACorp, Medscape, Medtronic, Michael J. Fox Foundation, Movement Disorder Society, National Institutes of Health (NIH), Neurocrine Biosciences, Neuroderm, Neuropore Therapies, Outcomes Insights, Parkinson Foundation, Peerview Press, Pennside Partners, Pfizer, Inc., Pharma Two B, Ltd, Phase Five Communications, Piper Jaffray & Co, Prexton Therapeutics, Projects in Knowledge, Putnam Associates, Quintiles, RMEI Medical Education for Better Outcomes, Sarepta Therapeutics, Schlesinger Associates, Scion Neurostim, LLC, Seagrove Partners, LLC, Slingshot Insights, Sunovion Pharmaceuticals, Inc., Sun Pharma, Teva Pharmaceutical Industries, US WorldMeds, Vista Research, WebMD, Windrose Consulting Group.. Dr. Hauser has received research support from AbbVie Inc., Acorda Therapeutics, AstraZeneca, Axovant Sciences , Biogen Inc., Cavion, Enterin Inc., Impax Laboratories, LLC., Intec Pharma Ltd, Jazz Pharmaceuticals, NeuroDerm Ltd., Lundbeck, Michael J Fox Foundation for Parkinson’s Research, F. Hoffman-La Roche, Dart NeuroScience LLC, Prexton Therapeutics, Revance Therapeutics Inc., Sunovion Pharmaceuticals, Parkinson’s Foundation .

Ready to register for the 2019 AAN Annual Meeting?

Related Courses

Saturday, May 4, 2019
7:00 AM-9:00 AM
C6 - Therapy of Movement Disorders: A Case-based Approach David Riley MD
9:30 AM-11:30 AM
C18 - Cerebellar and Afferent Ataxias: Diagnosis and Management Massimo Pandolfo MD, FAAN
1:30 PM-3:30 PM
C34 - Evaluating Tremor in the Office Andres Deik Acosta Madiedo MD
2:30 PM-3:15 PM
Dancing with Parkinson's Diviya Kaul MD
4:15 PM-5:30 PM
Hot Topics Plenary Session Eric Klawiter MD, FAAN

Sunday, May 5, 2019
7:00 AM-9:00 AM
C42 - The Dystonias: Diagnosis, Treatment and Update on Etiologies Rachel Saunders-Pullman MD
11:30 AM-6:30 PM
P1 - Poster Session 1
1:00 PM-3:00 PM
C51 - Balance and Gait Disorders Alfonso Fasano MD, PhD
3:30 PM-5:30 PM
C67 - Neurology Update II: Behavioral Neurology, Movement Disorders, and Neuro-ophthalmology Ralph Jozefowicz MD, FAAN, Adam Quick MD
C72 - Disordered Sleep in Common Neurologic Diseases: Traumatic Brain Injury, Stroke, and Parkinson’s Disease LynnMarie Trotti MD
N1 - Neuroscience in the Clinic: Child Neurology: Emerging Understanding of the Epilepsy-Movement Disorder Spectrum Across the Lifespan Deborah Hall MD, PhD, FAAN, Erika Augustine MD, FAAN
S10 - Biomarkers in Movement Disorders

Monday, May 6, 2019
7:00 AM-9:00 AM
C83 - Diagnosis and Treatment of Functional Movement Disorders Mark Hallett MD, FAAN
C87 - Skills Workshop: Clinical Usefulness of Botulinum Toxin for Spasticity (Registration Required) Allison Brashear MD, MBA, FAAN
11:30 AM-6:30 PM
P2 - Poster Session 2
1:00 PM-3:00 PM
C93 - Paroxysmal Movement Disorders Kailash Bhatia MD, FAAN
S16 - Huntington's Disease: From Bench to Clinical Trials
1:00 PM-5:30 PM
C105 - Skills Workshop: Clinical Uses of Botulinum Toxin for Dystonia (Registration Required) Diego Torres-Russotto MD, FAAN
3:30 PM-5:30 PM
C117 - Tourette Syndrome: Assessment and Management Tamara Pringsheim MD, FAAN
5:00 PM-5:45 PM
Careers in Movement Disorders Stanley Fahn MD, FAAN

Tuesday, May 7, 2019
7:00 AM-9:00 AM
C127 - Hyperkinetic Movement Disorders: Videodiagnosis and Treatment Steven Frucht MD
11:30 AM-6:30 PM
P3 - Poster Session 3
1:00 PM-3:00 PM
C137 - Deep Brain Stimulation I: Basic Principles and Programming in Movement Disorders Michael Pourfar MD
3:30 PM-5:30 PM
C155 - Deep Brain Stimulation II: Advanced Management in Movement Disorders and Applications Beyond Movement Disorders Leonard Verhagen Metman MD, PhD
IS2 - Invited Science: Movement Disorders Deborah Hall MD, PhD, FAAN

Wednesday, May 8, 2019
7:00 AM-9:00 AM
C168 - Parkinson's Disease Update Melissa Nirenberg MD, PhD, FAAN
C170 - Video EEG: Name That Spell Amy Crepeau MD
8:00 AM-8:45 AM
Complementary Therapies in Parkinson's Disease Veronica Santini MD, MA
11:30 AM-6:30 PM
P4 - Poster Session 4
1:00 PM-1:45 PM
Understanding the AAN's Latest Guidelines Tamara Pringsheim MD, FAAN
1:00 PM-3:00 PM
C179 - Nonmotor Manifestations of Parkinson's Disease I Jennifer Goldman MD, MS, FAAN
C185 - Actualización en trastornos del movimiento (Update in Movement Disorders) Andres Deik Acosta Madiedo MD
3:30 PM-5:30 PM
C196 - Nonmotor Manifestations of Parkinson's Disease II Jennifer Goldman MD, MS, FAAN
N5 - Neuroscience in the Clinic: Wearable Technology Eric Klawiter MD, FAAN, Deborah Hall MD, PhD, FAAN
S41 - Imaging in Movement Disorders

Thursday, May 9, 2019
7:00 AM-9:00 AM
C209 - Movement Disorders for the General Neurologist I: New Concepts in the Diagnosis and Management of Parkinson's Disease Irene Litvan MD, FAAN
11:30 AM-6:30 PM
P5 - Poster Session 5
1:00 PM-3:00 PM
C220 - Movement Disorders for the General Neurologist II: Tremor, Drug-induced Movement Disorders, RLS, and Ataxia Joohi Jimenez Shahed MD
3:30 PM-5:30 PM
C233 - Therapy in Neurology IV: Movement Disorders and Stroke David Dodick MD, FAAN
C234 - Movement Disorders for the General Neurologist III: Chorea, Dystonia, Myoclonus, Stereotypies, and Tics Shyamal Mehta MD, PhD
S53 - Movement Disorders: Genetics and Clinical Features
7:00 PM-10:00 PM
C240 - Case Studies: Unusual Movement Disorders Kailash Bhatia MD, FAAN

Friday, May 10, 2019
7:00 AM-9:00 AM
C246 - Hot Topics and Controversies in Parkinson's Disease Melissa Nirenberg MD, PhD, FAAN
1:00 PM-3:00 PM
C253 - Update in Movement Disorders Alfonso Fasano MD, PhD

Footer